Three-year outcome in a patient with Staphylococcus lugdunensis discitis.
The few reported cases of bone and joint infection by Staphylococcus lugdunensis indicate that the clinical manifestations are severe, the diagnosis elusive, and the treatment difficult. We report a case of lumbar discitis caused by Staphylococcus lugdunensis in a 67-year-old man receiving chemotherapy for stage III IgA lambda multiple myeloma. Treatment was with ofloxacin and pristinamycin for 1 year. Although he started to improve only 5 months after treatment initiation, the outcome was favorable. Follow-up at the time of this writing is 3 years.
Camacho
Mildreth
M
Rheumatology department, hĵpital de la Conception, Marseilles, France.
Guis
Sandrine
S
Mattei
Jean-Pierre
JP
Costello
Régis
R
Roudier
Jean
J
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015299:Discitis / Q000188:drug therapy / Q000209:etiology / Q000473:pathology*; D006801:Humans; D016867:Immunocompromised Host; D008159:Lumbar Vertebrae / Q000382:microbiology / Q000473:pathology*; D008297:Male; D008826:Microbial Sensitivity Tests; D009101:Multiple Myeloma / Q000188:drug therapy / Q000276:immunology; D015242:Ofloxacin / Q000627:therapeutic use; D025762:Pristinamycin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000150:complications / Q000188:drug therapy / Q000473:pathology*; D013210:Staphylococcus / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D025762:Pristinamycin; D015242:Ofloxacin